Atria Investments Inc Buys 393 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Atria Investments Inc boosted its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 19.2% during the 4th quarter, Holdings Channel reports. The firm owned 2,436 shares of the biotechnology company’s stock after buying an additional 393 shares during the quarter. Atria Investments Inc’s holdings in Ascendis Pharma A/S were worth $335,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ASND. Westfield Capital Management Co. LP raised its stake in Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after buying an additional 267,881 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Ascendis Pharma A/S by 9.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after buying an additional 155,971 shares in the last quarter. Groupama Asset Managment bought a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $60,000. Finally, ARS Investment Partners LLC grew its position in Ascendis Pharma A/S by 0.9% in the fourth quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock worth $36,549,000 after acquiring an additional 2,369 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ASND shares. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a report on Tuesday, February 18th. The Goldman Sachs Group lifted their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Evercore ISI boosted their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald raised their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $202.36.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock opened at $168.84 on Tuesday. The stock has a market cap of $10.25 billion, a price-to-earnings ratio of -23.78 and a beta of 0.62. The firm has a 50-day moving average of $138.88 and a two-hundred day moving average of $134.90. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. Research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.